IPO registrations (S-1, F-1) · Registrants
CITIUS ONCOLOGY, INC.
- SEC CIK
- 1851484 · filings on EDGAR ↗
- Former names
- TenX Keane Acquisition (2021–2024)
- Registration
- Form S-1, first filed 2021-05-19, last 2025-07-14; 2 initial registrations, 9 amendments
- Outcome
- Final prospectus filed 2022-10-14; declared effective 2022-10-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 11 COMMERCE DRIVE, 1ST FLOOR, Cranford, NJ 07016
- EIN
- 99-4362660
- Ticker
- CTOR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CITIUS ONCOLOGY, INC. on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2022-10-14, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $60,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TENK
- Lead underwriters
- Maxim Group
- Syndicate
- of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Citius Oncology, Inc. Fuzzy (name and state)
- Business registration: Citius Oncology, Inc. Fuzzy (name and state)
- Business registration: CITIUS ONCOLOGY, INC. Fuzzy (name and state)
- Business registration: CITIUS ONCOLOGY, INC. Fuzzy (name and state)
- SEC filer: CITIUS ONCOLOGY, INC. EXACT (CIK (EXACT))
- Person page: Dennis M Mcgrath Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Leonard L Mazur Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 20
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-05-19 | S-1 | S-1 (registration) | TenX Keane Acquisition | 0001493152-21-012185 ↗ |
| 2021-06-30 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-21-015601 ↗ |
| 2021-08-20 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-21-020860 ↗ |
| 2022-03-08 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-006313 ↗ |
| 2022-04-01 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-008828 ↗ |
| 2022-05-11 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-012880 ↗ |
| 2022-05-24 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-014854 ↗ |
| 2022-07-29 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-020683 ↗ |
| 2022-09-12 | S-1/A | S-1/A (amendment) | TenX Keane Acquisition | 0001493152-22-025658 ↗ |
| 2022-10-13 | EFFECT | EFFECT (declared effective) | TenX Keane Acquisition | 9999999995-22-003025 ↗ |
| 2022-10-14 | 424B4 | 424B4 (final prospectus) | TenX Keane Acquisition | 0001493152-22-028441 ↗ |
| 2024-07-12 | EFFECT | EFFECT (declared effective) | TenX Keane Acquisition | 9999999995-24-002146 ↗ |
| 2025-07-14 | S-1 | S-1 (registration) | CITIUS ONCOLOGY, INC. | 0001213900-25-063483 ↗ |
| 2025-07-14 | S-1/A | S-1/A (amendment) | CITIUS ONCOLOGY, INC. | 0001213900-25-063793 ↗ |
| 2025-07-16 | EFFECT | EFFECT (declared effective) | CITIUS ONCOLOGY, INC. | 9999999995-25-002269 ↗ |
| 2025-07-17 | 424B4 | 424B4 (final prospectus) | CITIUS ONCOLOGY, INC. | 0001213900-25-064848 ↗ |
| 2025-09-04 | EFFECT | EFFECT (declared effective) | CITIUS ONCOLOGY, INC. | 9999999995-25-002843 ↗ |
| 2026-01-12 | EFFECT | EFFECT (declared effective) | CITIUS ONCOLOGY, INC. | 9999999995-26-000150 ↗ |
| 2026-03-02 | EFFECT | EFFECT (declared effective) | CITIUS ONCOLOGY, INC. | 9999999995-26-000698 ↗ |
| 2026-06-05 | EFFECT | EFFECT (declared effective) | CITIUS ONCOLOGY, INC. | 9999999995-26-001912 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-12 | S-1/A | registration statement | $10.00 | 6,000,000 | $60,000,000 | Nasdaq TENK | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ | |
| 2022-10-14 | 424B4 | final prospectus | $10.00 | 6,000,000 | $60,000,000 | Nasdaq TENK | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| 10XYZ Management LLC | TenPercentOwner | 1 | 2022 | ||
| Hartzband Brian Shawn | Director | 1 | 2022 | ||
| Jiang Cathy | Director | 1 | 2022 | ||
| Mayersohn Joel David | Director | 6 | 2022–2025 | ||
| Yuan Xiaofeng | Director,Officer,TenPercentOwner | Chief Executive Officer | 1 | 2022 | |
| Zhang Dahe | Director,Officer,TenPercentOwner | Chief Financial Officer | 1 | 2022 | |
| Bartushak Jaime | Officer | Chief Financial Officer | 7 | 2024–2025 | |
| Citius Pharmaceuticals, Inc. | TenPercentOwner | 2 | 2024 | ||
| Czuczman Myron | Officer | Chief Medical Officer | 7 | 2024–2025 | |
| Dutia Suren G | Director | 6 | 2024–2025 | ||
| HOLUBIAK MYRON Z | Director; Director,Officer | Secretary | 7 | 2024–2025 | |
| Mazur Leonard L | Director,Officer | Chief Executive Officer | 7 | 2024–2025 | person page Fuzzy |
| MCGRATH DENNIS M | Director | 6 | 2024–2025 | person page Fuzzy | |
| Smith Robert Joseph | Director | 5 | 2024–2025 | ||
| Webb Carol | Director | 6 | 2024–2025 | ||
| Holuka Eugene Myron | Director | 6 | 2024–2025 | ||
| Peri Jonathan | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Citius Oncology, Inc. | NJ | State business registries | name and state |
| Business registration | Citius Oncology, Inc. | NJ | State business registries | name and state |
| Business registration | CITIUS ONCOLOGY, INC. | NJ | State business registries | name and state |
| Business registration | CITIUS ONCOLOGY, INC. | NJ | State business registries | name and state |
| IPO registrant | Citius Pharmaceuticals, Inc. | NJ | IPO registrations (S-1, F-1) | same street address and ZIP code, 11 COMMERCE DR 1ST FL 07016 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | CITIUS ONCOLOGY, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Citius Oncology, Inc. | NJ | Trademarks (USPTO) | name and state |
| Person page | Dennis M Mcgrath | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Leonard L Mazur | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NJ first:
- KOS PHARMACEUTICALS INC NJ
- NOVADEL PHARMA INC NJ
- ELITE PHARMACEUTICALS INC /NV/ NJ
- MEMORY PHARMACEUTICALS CORP NJ
- PHIBRO ANIMAL HEALTH CORP NJ
- PTC THERAPEUTICS, INC. NJ
- ADVANCED NUTRACEUTICALS INC NJ
- Ayala Pharmaceuticals, Inc. NJ
- INSMED Inc NJ
- Sonnet BioTherapeutics Holdings, Inc. NJ
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health